Debates in AML: First-Line Venetoclax vs Ivosidenib with Azacitidine

Speakers: 

Julia Manzo, DO, Hematology/Oncology Fellow - has nothing to disclose.

Dominick Patafio, PharmD, PGY2 Hematology/Oncology Resident - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Identify current preferred first-line therapies for IDH1-positive AML
• Describe the mechanism of action of ivosidenib and venetoclax
• Compare the benefits and downsides to ivosidenib and venetoclax in combination with azacitidine
• Critique design and data from the AGILE and VIALE-A trials
• Assess the most recent available data concerning ivosidenib and venetoclax in relapse/refractory AML

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP; Rajiv Panikkar, MD; Michele Long, BSN; Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None